



JAPAN TOBACCO INC.  
2-1, Toranomom 2-chome, Minato-ku  
Tokyo 105-8422 JAPAN  
Phone:03-3582-3111

**FOR IMMEDIATE RELEASE**

Tokyo, December 14, 2018

## **JT Agrees the Termination Date of its Licensing Agreements on Six Anti-HIV Drugs**

Japan Tobacco Inc. (JT) (TSE: 2914) announces today that the termination date of the license agreements with Gilead Sciences, Inc. (Gilead) and Torii Pharmaceutical Co., Ltd (Torii) (TSE: 4551) (collectively, the “Original Agreements”) regarding JT’s and Torii’s rights to six anti-HIV drugs<sup>1</sup> (Current HIV Drugs) in Japan is set for January 1, 2019. The termination of the Original Agreements was announced in a press release<sup>2</sup> on November 29, 2018.

From January 1, 2019 to the completion of transfer of the marketing approvals of the Current HIV Drugs in Japan to Gilead Sciences K.K., the Japanese subsidiary of Gilead, scheduled to be completed in 2019, JT will purchase the Current HIV drugs from Gilead and Torii will be responsible for the distribution of said drugs in Japan, under the terms and conditions for a provisional measure. Gilead Sciences K.K., the Japanese subsidiary of Gilead, will be responsible for providing information relating to said drugs to all medical institutions in Japan.

There is no expected impact on JT’s consolidated business results for the fiscal year ended December 2018.

###

*Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries. With close to 60,000 employees, it manufactures and sells some of the world’s best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets Ploom TECH, its tobacco vapor product, and various e-cigarette products under the Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit <https://www.jt.com/>.*

**Contact for Japan Tobacco Inc.:**  
Masahito Shirasu, General Manager  
Media and Investor Relations Division  
Japan Tobacco Inc. Tokyo: +81-3-5572-4292  
E-mail: [jt.media.relations@jt.com](mailto:jt.media.relations@jt.com)

- 
- <sup>1</sup> “Viread® Tablets 300mg” “Emtriva® Capsules 200mg” ”Truvada® Combination Tablets”  
“Stribild® Combination Tablets” “Genvoya® Combination Tablets”  
“Descovy® Combination Tablets LT/HT”
- <sup>2</sup> [https://www.jt.com/media/news/2018/pdf/20181129\\_E1.pdf](https://www.jt.com/media/news/2018/pdf/20181129_E1.pdf)